Related Experiment Video
Updated: Apr 18, 2026

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Anti-Glutamic Acid Decarboxylase 65 (Anti-GAD65) Autoimmune Encephalopathy: A Case of Diagnostic and Treatment
Naung Latt Htun1, Hsan Theingi Win1
1Internal Medicine, Suri Seri Begawan Hospital, Kuala Belait, BRN.
Abstract:
Anti-glutamic acid decarboxylase 65 (anti-GAD65) autoimmune encephalopathy is an uncommon but increasingly recognized cause of cognitive impairment and refractory seizures. We report a 69-year-old woman with a background of insulin-treated diabetes mellitus, hypertension, hypercholesterolemia, and prior hyperthyroidism, who presented with acute altered consciousness and cognitive dysfunction. Initial investigations excluded metabolic, infectious, vascular, and paraneoplastic causes. Cerebrospinal fluid (CSF) analysis showed mildly elevated protein without pleocytosis, and MRI brain demonstrated nonspecific periventricular T2/FLAIR hyperintensities. Thyroid antibodies were markedly elevated, raising suspicion for Hashimoto's encephalopathy; however, an extended autoimmune panel revealed strongly positive anti-GAD65 antibodies (50.9 nmol/L; reference <0.02). She was treated with intravenous immunoglobulin and pulsed methylprednisolone, with partial improvement but persistent slow mentation. Rituximab was planned, but follow-up was lost. This case highlights the diagnostic overlap between anti-GAD65 encephalitis and Hashimoto's encephalitis, underscores the importance of comprehensive antibody testing in unexplained encephalopathy, and illustrates the incomplete response to first-line immunotherapy.
More Related Videos
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Alzheimer's Disease: Treatment
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

